Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs

The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate the pandemic. Disruptions to healthcare systems and the management of chronic diseases has resulted in patients having difficulty seeing HCPs and receiving treatment, including for autoimmune and inflammatory conditions, especially as many of these immunological disorders require ongoing therapy. Immunological disorders whose treatment has been disrupted include psoriasis, rheumatoid arthritis, inflammatory bowel disease, and others. The key objectives of this report are to: assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices; understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent; quantify the impact of the pandemic on sales of key players in the immunology sector; determine how quickly key players will financially recover from the pandemic.

Scope

How patient appointments are conducted.

How treatment selection and administration has been affected.

Whether subsequent waves of infection are expected.

How the sales of key immunology drugs have been affected.

Key Highlights

Assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices.

Understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent.

Quantify the impact of the pandemic on sales of key players in the immunology sector.

Determine how quickly key players will financially recover from the pandemic.

Reasons to buy

The report will enable you to:

Develop business strategies by understanding the trends shaping and driving the immunology market in the US and 5EU.

Drive revenues by understanding the key trends and how companies are reacting during the pandemic in the US and 5EU immunology market.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Create effective strategies to counter disruption caused by the pandemic in order to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

AbbVie

Almirall

Amgen

Bausch Health

Eli Lilly

Janssen

Johnson & Johnson

Novartis

Pfizer

Regeneron

Roche

Sanofi

Takeda

UCB

Table of Contents

Table of Contents (PowerPoint Deck)

Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

2 Key Findings

3 Background & Methodology

3.1 Background, Objectives, and Scope

3.2 Methodology Overview

3.3 Physician Survey – Respondents Profile

4 Impact of COVID-19 on Patient Appointments

4.1 In-Person Appointments Delayed Due to the Pandemic

4.2 Patient Appointments Moved to Telemedicine

4.3 Newly Diangosed Patients vs. Referred Patients

5 History of Immunology Drugs in Treating COVID-19 Infection

5.1 Anti-IL-6 Biologics

5.2 Anti-TNF Biologics

5.3 JAK Inhibitors

6 Impact of COVID-19 on Prescription Habits

6.1 Pre-pandemic Prescription Habits

6.2 Prescription Habits During the Pandemic (May-Nov 2020)

6.3 Prescription of Biologics vs. Oral Therapies

6.4 Treatment Initiation Delays

6.5 Treatment Delays of Current Therapies

6.6 Expected Rebound of Patient Apppointments and Treatment Initiaitons

7 Expectation for a Subsequent Wave

7.1 Timing and Impact of a Subsequent Wave

8 Impact of COVID-19 on Immunology Drug Sales

8.1 Total Sales of Immunology Drugs in the 6MM, Q1 2020-Q42022

8.2 Certain Drug Classes Suffered During the Pandemic

8.3 Sales of Immunology Drugs Have Been Resilient Despite the Pandemic

8.4 Impact of COVID-19 on the Sales of SC Anti-TNF Biologics Differ Between US and 5EU

8.5 IV Anti-TNF Biologics Struggled During the Initial Outbreak

8.6 Anti-TNF Biosimilars Set to Recover by Q4 2020 from Pandemic Dip

8.7 Future Outlook for IL-5 Biologics Similar in US and 5EU Despite Differing Pandemic Performance

8.8 JAK Inhibitors on a Promising Trajectory in the US and 5EU

9 Appendix

9.1 Bibliography

9.2 Primary Research

9.3 Methodology

9.4 About the Authors

10 Contact Us

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports